logo
  

USANA Health Sciences Lowers FY21 Outlook, Shares Down 3%

Shares of USANA Health Sciences Inc. (USNA) slipped 3% in extended session on Thursday after the company lowered its financial outlook for fiscal year 2021.

The company now expects full year 2021 earnings of $5.80 to $6.00 per share and revenues of $1.18 billion to $1.20 billion. Previously, the company expected earnings of $6.15 to $6.50 per share on revenues of $1.24 to $1.28 billion.

The company currently anticipates third quarter sales of $265 million to $270 million and earnings of $1.28 and $1.33 per share.

"Our sales results for the third quarter have been softer than we anticipated, largely because of increased disruptions and lockdowns in several of our markets due to the escalation of the COVID-19 pandemic," said Kevin Guest, Chief Executive Officer and Chairman of the Board.

USNA closed Thursday's trading at $87.46, down $0.05 or 0.06%, on the Nasdaq. The stock further slipped $2.69 or 3.08% in the after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Privately-held biotechnology company On Target Laboratories, Inc. announce that the U.S. Food and Drug Administration or FDA, has approved Cytalux (pafolacianine) for adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions. Cytalux is the first targeted fluorescent imaging agent that illuminates ovarian cancer intraoperatively. The Federal Trade Commission or FTC has ordered Walmart, Amazon, Kroger and certain other large wholesalers and suppliers to provide information to help it study causes of supply chain disruptions. The agency has launched an inquiry to find the reasons for empty shelves and exorbitant prices. Along with Walmart, Amazon.com, and Kroger, the order has been sent to C&S Wholesale Grocers, Associated.. Covid vaccine maker Moderna Inc.'s Chief Executive Stéphane Bancel has predicted that existing COVID-19 vaccines will be much less effective against Omicron than earlier strains, according to the Financial Times.
Follow RTT